Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Dermatology
Published in: BMC Dermatology 1/2015

Open Access 01-12-2015 | Case report

Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report

Authors: Jennifer Goldstein, Anisha B. Patel, Jonathan L. Curry, Vivek Subbiah, Sarina Piha-Paul

Published in: BMC Dermatology | Issue 1/2015

Login to get access

Abstract

Background

Novel targeted agents have been increasingly developed and tested in clinical trials over the past 5–10 years, many with unknown and unanticipated side effects. We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib–associated photoallergic dermatitis while enrolled on a phase 1 clinical trial.

Case presentation

A 51-year-old Caucasian female with poorly differentiated, metastatic follicular thyroid carcinoma presented with a cutaneous eruption that developed over 3 to 4 days while treated on phase 1 clinical trial with vandetanib-based therapy. Given the concern for photoallergic dermatitis, vandetanib was discontinued and supportive care provided including topical and oral steroid administration. Her cutaneous eruption improved and she was successfully re-challenged with vandetanib.

Conclusion

Tyrosine kinase inhibitors, such as typo-vandetinib, with various therapeutic targets have come to the forefront of oncologic therapy in recent years. It is important to have a better understanding of the side effect profile and management in order to anticipate adverse events and maintain patient safety in future clinical trials.
Literature
1.
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645–55.PubMed
2.
Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284–90.PubMed
3.
4.
Huang X, Patel S, Ahmed N, Seiter K, Liu D. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther. 2009;2:215–9.PubMedPubMedCentral
5.
Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf. 2007;6(4):431–43.CrossRefPubMed
6.
Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25(5):345–72.CrossRefPubMed
7.
Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(4):1125–33.CrossRefPubMed
8.
Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2005;11(9):3369–76.CrossRefPubMed
9.
Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2008;3(4):386–93.CrossRefPubMed
10.
Chang CH, Chang JW, Hui CY, Yang CH. Severe photosensitivity reaction to vandetanib. J Clin Oncol. 2009;27(27):e114–5.CrossRefPubMed
11.
Kong HH, Fine HA, Stern JB, Turner ML. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol. 2009;145(8):923–5.CrossRefPubMedPubMedCentral
12.
Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418–20.CrossRefPubMed
13.
Fava P, Quaglino P, Fierro MT, Novelli M, Bernengo MG. Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther. 2010;23(5):553–5.CrossRefPubMed
Metadata
Title
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report
Authors
Jennifer Goldstein
Anisha B. Patel
Jonathan L. Curry
Vivek Subbiah
Sarina Piha-Paul
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Dermatology / Issue 1/2015
Electronic ISSN: 1471-5945
DOI
https://doi.org/10.1186/s12895-015-0022-1

Other articles of this Issue 1/2015

BMC Dermatology 1/2015 Go to the issue

Research article

Magnitude and associated factors of Atopic dermatitis among children in Ayder referral hospital, Mekelle, Ethiopia

Research article

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers

Research article

Exploring the association between Morgellons disease and Lyme disease: identification of Borrelia burgdorferi in Morgellons disease patients

Case report

Small lymphocytic lymphoma with florid perniosis-like features: a case report

Research article

Adherence to drug treatments and adjuvant barrier repair therapies are key factors for clinical improvement in mild to moderate acne: the ACTUO observational prospective multicenter cohort trial in 643 patients

Reviewer acknowledgement

BMC Dermatology reviewer acknowledgement, 2014